The relationship between mean platelet volume and metabolic syndrome in patients with type 2 diabetes mellitus

A retrospective study

Qinpei Ding, MMa, Fangwei Wang, MMb, Xintong Guo, MMa, Min Liang, MDa,∗

Abstract
This study aimed to investigate the association between mean platelet volume (MPV) and metabolic syndrome (MetS) in patients with type 2 diabetes mellitus (T2DM). Data for 1240 patients with T2DM admitted to the Department of Endocrinology at the First Affiliated Hospital of Guangxi Medical University between January 1, 2017 and June 1, 2020 were collected retrospectively via electronic medical records, including demographic information, complete blood count, lipid profile, and glucose metabolism indexes. MetS was defined according to the Chinese Diabetes Society. Among the 1240 patients enrolled, 873 (70.40%) had MetS. MPV was significantly higher in patients with MetS (P < .001). For individual MetS components, MPV was significantly higher in the presence of abdominal obesity (P = .013) and hypertriglyceridemia (P = .026), but did not differ in the presence of elevated blood pressure (P = .330) or low high-density lipoprotein cholesterol (P = .790). Moreover, MPV was independently associated with MetS after adjustment for sex, smoking, alcohol drinking, white blood cell count, fasting C-peptide, and body mass index (odds ratio 1.174, 95% confidence interval 1.059–1.302). The odds ratio for MetS in the highest tertile, compared with the lowest MPV tertile, was 1.724 (95% confidence interval 1.199–2.479, P for trend = .003) after multiple adjustment. In stratified analyses, the positive correlation of MPV with MetS was significant only in patients who were older, male, or overweight, or who had poor glycemic control. In conclusion, high MPV was positively associated with the presence of MetS in patients with T2DM, particularly older, male, or overweight patients, or those with poor glycemic control.

Abbreviations: BMI = body mass index, CI = confidence interval, DBP = diastolic blood pressure, HDL-C = high-density lipoprotein cholesterol, HOMA-IR = homeostasis model assessment of insulin resistance, LDL-C = low-density lipoprotein cholesterol, MetS = metabolic syndrome, MPV = mean platelet volume, OR = odds ratio, SBP = systolic blood pressure, T2DM = type 2 diabetes mellitus.

Keywords: mean platelet volume, metabolic syndrome, type 2 diabetes mellitus

1. Introduction
Platelets play a crucial role in the development of atherothrombosis, a major contributor to cardiovascular events.[1] Platelet activation and aggregation potential, the essential components of atherosclerosis, are central processes in the pathophysiology of cardiovascular diseases. Larger platelets are enzymatically and metabolically more active and have greater prothrombotic potential than smaller ones.[2] Mean platelet volume (MPV) is a widely used marker of platelet size and activity, which is easily and inexpensively measured. Elevated MPV is associated with accelerated thrombopoiesis and an increased risk of cardiovascular diseases.[3–5]

Metabolic disorders such as dyslipidemia, obesity, and elevated blood pressure and glucose are risk factors for cardiovascular diseases.[6] The presence of these metabolic disorders is responsible for the prothrombotic tendency, at least in part because of platelet hyperactivation.[7] Numerous studies have strongly correlated these clinical features with platelet activation, as measured by MPV.[8–15] For example, a retrospective analysis of 13,021 patients has shown a significantly higher MPV in patients with diabetes (8.2 vs 8.06 fL), and a significant correlation between MPV and glucose.[10] The authors have concluded that MPV is strongly and independently associated with the presence and severity of diabetes. Another large sample study of 80,545 patients without cardiovascular diseases and hypertension has shown that elevated MPV is associated with prehypertension.[16] Although a causative relationship between MPV and these metabolic disorders could not be addressed, these findings suggest that elevated MPV levels may link metabolic disorders and cardiovascular diseases.

Metabolic syndrome (MetS) is a group of cardiometabolic disorders, including central obesity, dyslipidemia, elevated blood
pressure, and hyperglycemia.\textsuperscript{[17,18]} A relationship may potentially exist between MPV and MetS. Additionally, insulin resistance plays a central role in the pathogenesis of MetS,\textsuperscript{[19]} and insulin resistance is associated with increased platelet activity.\textsuperscript{[17,20]} To date, however, few studies have investigated the association between MPV and MetS, and the results are controversial.\textsuperscript{[4,10,21–24]} Further studies are warranted to validate a potential association. This retrospective study aimed to evaluate the relationship between MPV and MetS in patients with type 2 diabetes mellitus (T2DM).

2. Materials and methods

2.1. Research participants

This was a retrospective case-control study. Inpatients admitted to the Department of Endocrinology at the First Affiliated Hospital of Guangxi Medical University between January 1, 2017 and June 1, 2020 were reviewed via electronic medical records. The inclusion criteria consisted of the following:

1. diagnosis with T2DM (on the basis of the diagnosis criteria of the World Health Organization in its published report of 1999\textsuperscript{[23]} without limitation of the duration of T2DM and the medications patients took; and
2. aged ≥18 years.

The exclusion criteria included the following:

1. hematological diseases;
2. severe inflammatory or infectious diseases;
3. acute coronary syndrome or severe heart failure (New York Heart Association class III to IV);\textsuperscript{[26]}
4. hepatic or renal dysfunction (alanine aminotransferase and aspartate aminotransferase above 2 times the upper limit of normal, and creatinine >2.5 mg/dL, respectively);
5. malignancy or other critical diseases;
6. lactation or pregnancy in women; and
7. lack of necessary laboratory or physical examination data.

2.2. Data collection

For the included patients, clinical data were extracted from the electronic medical records, including age, sex, smoking (yes/no), alcohol drinking (yes/no), duration of T2DM, height, weight, waist circumference, hypertension (yes/no), systolic blood pressure (SBP), diastolic blood pressure (DBP), complete blood count, lipid profile, and glucose metabolism indexes. Blood samples were taken from a peripheral vein after an 8 to 12 hours overnight fast. Complete blood counts were measured with an automatic analyzer (Hitachi P800). Serum lipids and fasting plasma glucose were measured with enzymatic assays with an automatic analyzer (Hitachi P800). Serum lipids and fasting C-peptide were used to calculate HOMA-IR. In patients with repeated hospitalization, the first medical record was used.

2.3. Definitions

MetS was defined according to the Chinese criteria\textsuperscript{[28]} as presentation of 3 or more of the following:

1. abdominal obesity: waist circumference ≥90 cm for men or ≥85 cm for women;
2. elevated blood pressure: SBP ≥130 mm Hg or DBP ≥85 mm Hg, or current use of antihypertensive medications;
3. hypertriglyceridemia: triglyceride ≥1.7 mmol/L;
4. low high-density lipoprotein cholesterol (HDL-C): HDL-C <1.04 mmol/L; and
5. hyperglycemia: fasting plasma glucose ≥6.1 mmol/L, or postprandial 2 hours plasma glucose ≥7.8 mmol/L, or previously diagnosed diabetes.

All patients had T2DM and, by definition, met the criteria for hyperglycemia. Overweight and obesity were defined as 24 ≤BMI <28 kg/m\textsuperscript{2} and BMI ≥28 kg/m\textsuperscript{2}, respectively.\textsuperscript{[29]}

2.4. Ethics statement

The study was conducted in accordance with the principles of Declaration of Helsinki, and was reviewed and approved by the Medical Ethics Committee of the First Affiliated Hospital of Guangxi Medical University [2020 (KY-E-096)]. Informed consent was exempted because of the nature of the retrospective research.

2.5. Statistical analysis

Statistical analyses were performed in SPSS software (version 17.0). The normality of the distribution of continuous variables was assessed with the Kolmogorov–Smirnov test. Continuous variables with a normal distribution are presented as mean±SD and were analyzed by independent-sample t tests or one-way analysis of variance, whereas data with non-normal distributions are expressed as median (and interquartile range) and were analyzed with Mann–Whitney U tests. Categorical variables are given as frequency with percentage and were compared with \chi\textsuperscript{2} tests. Associations between MPV and other variables were examined with Pearson or Spearman correlation coefficients. A logistic regression model was used to assess the odds ratios (ORs) and 95% confidence intervals (CIs) of having MetS, with adjustment for potential confounders. Tests of linear trends across increasing tertile of MPV were performed by assigning a grade (1, 2, or 3) to the corresponding tertile and treating it as a continuous variable. A two-sided \( P \) value <.05 was considered statistically significant.

3. Results

A total of 3122 patients were screened; of those patients, 1240 were enrolled. A flow diagram of the excluded and included patients is provided in Figure 1. Among the 1240 patients, 873 (70.40%) had MetS. The mean age of the study population was 53 years (range 19–90 years), and 791 (63.79%) were male. As expected, patients with MetS had higher BMI, waist circumference, SBP, DBP, serum triglycerides, numbers of MetS components, HOMA-IR, and lower HDL-C than patients without MetS.
Demographic and clinical characteristics of the patients.

| Variables                        | Without MetS       | With MetS        | P     |
|----------------------------------|--------------------|------------------|-------|
| Age (yr)                         | 53.83 ± 12.46      | 53.36 ± 13.22    | .561  |
| Male sex                         | 221 (58.5)         | 588 (69.4)       | .007  |
| Diabetic duration (yr)           | 3 (1, 10)          | 4 (1, 10)        | .144  |
| Smoking, yes                     | 94 (24.9)          | 307 (34.6)       | .001  |
| Alcohol drinking, yes            | 84 (22.2)          | 271 (30.6)       | .013  |
| BMI (kg/m²)                      | 22.21 ± 3.28       | 26.10 ± 3.98     | < .001|
| Waist circumference (cm)         | 81.32 ± 9.05       | 92.93 ± 10.57    | < .001|
| Hypertension, yes                | 91.24 (1.1)        | 533 (80.1)       | < .001|
| SBP (mm Hg)                      | 128.62 ± 20.20     | 137.63 ± 21.40   | < .001|
| DBP (mm Hg)                      | 75.40 ± 11.16      | 82.62 ± 12.94    | < .001|
| White blood cell count (×10³/μL)| 6.93 ± 1.91        | 7.38 ± 2.10      | < .001|
| Red blood cell count (×10³/L)    | 4.64 ± 0.66        | 4.72 ± 0.75      | .001  |
| Platelet count (×10³/μL)         | 244.50 ± 72.84     | 244.46 ± 68.75   | .993  |
| Plateletcrit                     | 0.15 ± 0.03        | 0.15 ± 0.02      | .276  |
| MPV (fL)                         | 8.81 ± 1.60        | 9.34 ± 1.57      | < .001|
| Total cholesterol (mmol/L)       | 4.89 ± 1.32        | 4.88 ± 1.42      | .902  |
| Triglyceride (mmol/L)            | 1.16 ± 0.56        | 2.21 ± 1.47      | < .001|
| HDL-C (mmol/L)                   | 1.22 ± 0.34        | 0.97 ± 0.27      | < .001|
| LDL-C (mmol/L)                   | 3.03 ± 1.10        | 2.91 ± 1.05      | .060  |
| HbA1c                            | 9.59 ± 2.79        | 9.26 ± 2.43      | .057  |
| Fasting plasma glucose (mmol/L)  | 7.17 ± 3.13        | 7.45 ± 2.90      | .136  |
| Fasting C-peptide (ng/mL)        | 1.22 (0.51, 2.18)  | 2.09 (1.10, 2.96)| < .001|
| Number of components of MetS     | 1.66 ± 0.49        | 3.65 ± 0.89      | < .001|
| HOMA-IR                          | 1.15 (0.50, 2.00)  | 1.90 (1, 3)      | < .001|

**Table 1**

Mean platelet volume levels (fL) according to the presence or absence of individual components of metabolic syndrome except hyperglycemia.

| Components                         | Absent     | Present    | P     |
|------------------------------------|------------|------------|-------|
| Abdominal obesity                  | 8.99 ± 1.56| 9.27 ± 1.55| .013  |
| Elevated blood pressure            | 9.09 ± 1.61| 9.19 ± 1.60| .330  |
| Low HDL-C                          | 9.15 ± 1.50| 9.17 ± 1.68| .790  |
| Hypertriglyceridemia               | 9.08 ± 1.66| 9.29 ± 1.52| .026  |

**Table 2**
HOMA-IR was calculated on the basis of fasting C-peptide and, therefore, was also excluded to avoid multicollinearity. MPV was shown to be independently associated with MetS after adjustment for sex, smoking, alcohol drinking, white blood cell count, fasting C-peptide, and BMI (odds ratio [OR] 1.174, 95% CI 1.059–1.302, Fig. 3). After tertile classification of MPV, the risk of having MetS increased progressively across the lowest to the highest tertiles of MPV, with ORs of 1.559 (95% CI 1.164–2.089), and 2.500 (95% CI 1.816–3.442), respectively (P for trend <.001), after adjustment for sex, smoking, alcohol drinking, and white blood cell count (Model 1, Table 3). After further adjustment for fasting C-peptide, the ORs did not substantially change (Model 2). After additional control for BMI, the ORs were mildly attenuated (Model 3). In stratified analyses, the positive association remained only in patients who were older than 60 years or, male, and who had poor glycemic control (HbA1c ≥ 9%) or were overweight (24 ≤ BMI < 28 kg/m²) (Table 3).

4. Discussion
In the present study, we found that higher MPV was associated with an increased risk of MetS in patients with T2DM,

![Figure 2. Correlation between mean platelet volume and metabolic parameters in patients with type 2 diabetes mellitus. HOMA-IR = homeostasis model assessment of insulin resistance.](image-url)

![Figure 3. Logistic regression analysis of metabolic syndrome risk factors in patients with type 2 diabetes mellitus.](image-url)
particularly among those who were older, male, or overweight, or who had poor glycemic control. To our knowledge, this is the first study investigating the complex relationship between MPV and MetS in the setting of T2DM.

The positive association between MPV and MetS in our study is consistent with findings from several previous reports. For example, a study of 345 patients by Tavil et al. has reported higher MPV values in patients with MetS referred for coronary angiography than in those without MetS, and that MetS is independently associated with MPV. Another study on 200 patients with MetS and 100 age- and sex-matched control subjects by Farah and Khamisy-Farah has shown a positive correlation between MPV and the presence and severity of MetS. Larger platelets, as measured by MPV, contain more denser granules and adhesion receptors, produce more serotonin and thromboglobulin, and show greater prothrombotic potential.

In stratified analyses, we also found that MPV was associated with MetS in patients who were older or overweight, or who had poor glycemic control. MPV has been suggested to vary according to age and to increase with aging. Older individuals usually show deteriorated cardiovascular homeostasis and severe metabolic disturbances, followed by increased platelet activity. Insulin resistance is a crucial mechanism underlying MetS. We found that MPV was positively correlated with insulin resistance, as measured by HOMA-IR, in agreement with the results of 2 previous studies. Hence, insulin resistance might plausibly link MPV and MetS.

Despite the above findings, several studies have reported an inverse association between MPV and MetS, only in women but not men. The inverse association among these studies was explained as follows: the platelet mass (platelet count × MPV) remained constant, and the platelet count was positively associated with MetS. Hence, the inverse association between MPV and MetS was subordinate to the positive association of platelet count with MetS. However, our study indicated that the platelet count in patients with MetS did not differ from that in patients without MetS. Furthermore, all patients in our study had T2DM, and a lack of an inverse relationship between MPV and platelet count has been reported in patients with T2DM (increased MPV and platelet count together). The differences according to sex were explained by different lifestyles (i.e., lower smoking and alcohol drinking rates in women than men), and a higher fat percentage in women than in men with the same BMI.

In the present study, however, a positive association was observed between MPV and MetS in men but not women after adjustment for potential confounding factors, such as smoking and alcohol drinking. Thus, the potential sex effects of MPV on MetS must be elucidated further. In addition, some studies did not find that having MetS was associated with a significant difference in MPV values. These differences across studies may be explained in part by several factors such as the selection criteria (i.e., general population or diabetic patients), diagnostic criteria for MetS, race, and age (i.e., pre-pubertal children or older adults), thus suggesting that the association between MPV and MetS deserves further scrutiny.

In stratified analyses, we also found that MPV was associated with MetS in patients who were older or overweight, or who had poor glycemic control. MPV has been suggested to vary according to age and to increase with aging. Older individuals usually show deteriorated cardiovascular homeostasis and severe metabolic disturbances, followed by increased platelet activity. Insulin resistance is a crucial mechanism underlying MetS. We found that MPV was positively correlated with insulin resistance, as measured by HOMA-IR, in agreement with the results of 2 previous studies. Hence, insulin resistance might plausibly link MPV and MetS.

Despite the above findings, several studies have reported an inverse association between MPV and MetS, only in women but not men. The inverse association among these studies was explained as follows: the platelet mass (platelet count × MPV) remained constant, and the platelet count was positively associated with MetS. Hence, the inverse association between MPV and MetS was subordinate to the positive association of platelet count with MetS. However, our study indicated that the platelet count in patients with MetS did not differ from that in patients without MetS. Furthermore, all patients in our study had T2DM, and a lack of an inverse relationship between MPV and platelet count has been reported in patients with T2DM (increased MPV and platelet count together). The differences according to sex were explained by different lifestyles (i.e., lower smoking and alcohol drinking rates in women than men), and a higher fat percentage in women than in men with the same BMI.

In the present study, however, a positive association was observed between MPV and MetS in men but not women after adjustment for potential confounding factors, such as smoking and alcohol drinking. Thus, the potential sex effects of MPV on MetS must be elucidated further. In addition, some studies did not find that having MetS was associated with a significant difference in MPV values. These differences across studies may be explained in part by several factors such as the selection criteria (i.e., general population or diabetic patients), diagnostic criteria for MetS, race, and age (i.e., pre-pubertal children or older adults), thus suggesting that the association between MPV and MetS deserves further scrutiny.

In stratified analyses, we also found that MPV was associated with MetS in patients who were older or overweight, or who had poor glycemic control. MPV has been suggested to vary according to age and to increase with aging. Older individuals usually show deteriorated cardiovascular homeostasis and severe metabolic disturbances, followed by increased platelet activity. Insulin resistance is a crucial mechanism underlying MetS. We found that MPV was positively correlated with insulin resistance, as measured by HOMA-IR, in agreement with the results of 2 previous studies. Hence, insulin resistance might plausibly link MPV and MetS.
but not in obese (BMI ≥ 28 kg/m²) patients. This result is consistent with findings from a previous study of 920 patients (BMI ≥ 30 kg/m²) by Kutlucan et al, in which MPV did not differ between patients with versus without MetS.[38] The authors offered some explanations that might also account for our results. When the BMI was sufficiently high, the effect of BMI increment and association of MetS components reduced to an insignificant level, although the BMI remained significantly different.[38] This explanation appears to be credible and indirectly supports the close relationship between MPV and obesity. In our study, MPV was positively associated with MetS only in patients with poor glycemic control. Hyperglycemia leads to increased plasma osmotic pressure, thus resulting in osmotic swelling of platelet and elevated MPV.[10] A previous study[8] has reported decreased MPV during a 3-month follow-up in patients with diabetes who achieved improved glycemic control. The stronger association of MPV with MetS among patients with poor glycemic control suggests that good glycemic control may be helpful in decreasing platelet activity, thereby decreasing the incidence of cardiovascular events.

This study appears to be the first to investigate the complex relationship between MPV and MetS in the setting of T2DM. However, the lack of prior publications on this topic might be due to a lack of clinical significance. More studies on this topic should be performed in the future. Our study also has several limitations. First, a causal relationship between MPV and MetS could not be identified because of the case–control design. Second, the times between blood sample collection and analysis of the blood count (usually within 3 hours) may have differed among patients. Platelet volume increases over time in EDTA, the anticoagulant (usually within 3 hours) may have differed among patients. Between blood sample collection and analysis of the blood count, swelling in EDTA should not have impaired the robustness of our findings. Third, all patients in our study were inpatients with T2DM, and those with severe complications were excluded, thus resulting in limited generalizability of our findings. Additionally, some potential confounding factors such as the use of medications (i.e., aspirin, clopidogrel, oral hypoglycemic agents or insulin, or oral contraceptives),[42] coexisting cardiovascular diseases,[5] diabetic complications, the menstruation status of women, and physical activity[43] were not considered.

5. Conclusions
In summary, MPV was independently associated with MetS in patients with T2DM. The association of MPV with MetS was stronger in patients who were overweight, male, or older, or had poor glycemic control. Our findings suggest that in patients with T2DM, MPV may be another characteristic of MetS and may potentially be used as a surrogate indicator for MetS in clinical practice.

Acknowledgments
The authors gratefully appreciated the team of the Department of Medical Statistics in Guangxi Medical University for their work in the area of statistics in this study.

Author contributions
Analyzed and interpreted the data: DQP, GXT.

Collected data: DQP, GXT.
Conceived and designed the study: LM, DQP, GXT.
Conceptualization: Qinpei Ding, Fangwei Wang, Min Liang.
Data curation: Qinpei Ding, Xintong Guo.
Formal analysis: Qinpei Ding, Fangwei Wang.
Review and edit the manuscript: LM.
Software: Qinpei Ding, Fangwei Wang.
Supervision: Min Liang.
Validation: Qinpei Ding.
Writing – original draft: Qinpei Ding.
Writing – review & editing: Min Liang.
Wrote the manuscript: DQP.

References
[1] Davi G, Patrano C. Platelet activation and atherothrombosis. New Engl J Med 2007;357:2482–94.
[2] Noris P, Melazzini F, Balduni CL. New roles for mean platelet volume measurement in the clinical practice? Platelets 2016;27:607–12.
[3] Du J, Wang Q, He B, et al. Association of mean platelet volume and platelet count with the development and prognosis of ischemic and hemorrhagic stroke. Int J Lab Hematol 2016;38:233–9.
[4] Sansanayudh N, Muntham D, Yamwong S, et al. The association between mean platelet volume and cardiovascular risk factors. Eur J Intern Med 2016;30:37–42.
[5] Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume (MPV) with the risk and prognosis of cardiovascular diseases. Int J Clin Pract 2009;63:1509–15.
[6] Collaboration TGoMRFFCD. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol 2014;2:634–47.
[7] Bzaze C, Russo I. Influence of cardiometabolic risk factors on platelet function. Int J Mol Sci 2020;21:623.
[8] Demirtunc R, Duman D, Basar M, et al. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. J Diabetes Complications 2009;23:89–94.
[9] Coban E, Yilmaz A, Sari R. The effect of weight loss on the mean platelet volume in obese patients. Platelets 2007;18:212–6.
[10] Shah B, Sha D, Xie D, et al. The relationship between diabetes, metabolic syndrome, and platelet activity as measured by mean platelet volume: the National Health And Nutrition Examination Survey, 1999–2004. Diabetes Care 2012;35:1074–8.
[11] Varol E, Aksoy F, Bas HA, et al. Mean platelet volume is elevated in obese patients with low high-density lipoprotein cholesterol. Angiology 2013;65:733–6.
[12] Coban E, Ozdogan M, Yaziacioglu G, et al. The mean platelet volume in patients with obesity. Int J Clin Pract 2005;59:981–2.
[13] Varol E, Akcay S, Ildi A, et al. Mean platelet volume in patients with prehypertension and hypertension. Clin Hemorheol Microcirc 2010;45:67–72.
[14] Guven A, Calisik M, Cifcio O, et al. Increased platelet activation and inflammatory response in patients with masked hypertension. Blood Coagul Fibrinolysis 2013;24:170–4.
[15] Wang T, Xu J, Fu L, et al. Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients. Int J Clin Pract 2020;74:e13508.
[16] Cao X, Xie X, Zhou J, et al. Increased platelet volume in a general population with prehypertension: a cross-sectional study of 80 545 participants from China. Hypertens Res 2012;35:993–8.
[17] Mendrick DL, Diehl AM, Topor LS, et al. Metabolic syndrome and associated diseases: from the bench to the clinic. Toxicol Sci 2018;162:36–42.
[18] Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep 2018;20:12.
[19] Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol 2013;3:1–38.
[20] Nardin M, Verdoa M, Barbieri L, et al. Impact of metabolic syndrome on mean platelet volume and its relationship with coronary artery disease. Platelets 2019;30:615–23.
[21] Park BJ, Shin JY, Lee HR, et al. The relationship of platelet count, mean platelet volume with metabolic syndrome according to the criteria of the American Association of Clinical Endocrinologists: a focus on gender differences. Platelets 2012;23:45–50.

[22] Yang XJ, Zhang LY, Ma QH, et al. Platelet parameters in Chinese older adults with metabolic syndrome. Endocr Connect 2020;9:696–704.

[23] Tavil Y, Sen N, Yazici HU, et al. Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res 2007;120:245–50.

[24] Aypak C, Türedi O, Bircan MA, et al. Could mean platelet volume among complete blood count parameters be a surrogate marker of metabolic syndrome in pre-pubertal children? Platelets 2014;25:393–8.

[25] Alberti K, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Diabet Med 1999;16:539–53.

[26] McMurray JJ, Adamsopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803–69.

[27] Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998;21:2191–2.

[28] Society CD. China guideline for type 2 diabetes (2017). Chin J Diabetes Mellitus 2018;104:67.

[29] Hu L, Huang X, You C, et al. Prevalence of overweight, obesity, abdominal obesity and obesity-related risk factors in southern China. PLoS One 2017;12:e0183934.

[30] Farah R, Khamsiy-Farah R. Significance of MPV, RDW with the presence and severity of metabolic syndrome. Exp Clin Endocrinol Diabetes 2015;123:567–70.

[31] Ayas Z, Can U. Alteration of mean platelet volume in the pathogenesis of acute ischemic stroke: cause or consequence? Ideggyogy Sz 2018;71:49–56.

[32] Said S, Mukherjee D, Whayne TF. Interrelationships with metabolic syndrome, obesity and cardiovascular risk. Curr Vasc Pharmacol 2016;14:415–25.

[33] Budak YU, Polat M, Huysal K. The use of platelet indices, plateletcrit, mean platelet volume and platelet distribution width in emergency non-traumatic abdominal surgery: a systematic review. Biochem Med (Zagreb) 2016;26:178–93.

[34] Fan GQ, Qin RR, Li YH, et al. Endothelial cells microparticle-associated protein disulfide isomerase promotes platelet activation in metabolic syndrome. Oncotarget 2016;7:83231–40.

[35] Varol E, Akcay S, Ozaydin M, et al. Mean platelet volume is associated with insulin resistance in non-obese, non-diabetic patients with coronary artery disease. J Cardiol 2010;56:154–8.

[36] Elsherbiny IA, Shoukry A, El Tahliwai MA. Mean platelet volume and its relation to insulin resistance in non-diabetic patients with slow coronary flow. J Cardiol 2012;59:176–81.

[37] Zhao F, Yan Z, Meng Z, et al. Relationship between mean platelet volume and metabolic syndrome in Chinese patients. Sci Rep 2018;8:14574.

[38] Kuthucan A, Bulur S, Ke S, et al. The relationship between mean platelet volume with metabolic syndrome in obese individuals. Blood Coagul Fibrinol 2012;23:388–90.

[39] Lippi G, Salvagno GL, Targher G, et al. Relationship between mean platelet volume and biochemical components of the metabolic syndrome. Clin Drug Investig 2007;27:731–2.

[40] Lippi G, Meschi T, Borghi L. Mean platelet volume increases with aging in a large population study. Thromb Res 2012;129:e159–60.

[41] Costantino S, Paneni F, Cosentino F. Ageing, metabolism and cardiovascular disease. J Physiol 2016;594:2061–73.

[42] Arachchilage DRJ, Laffan M. Can mean platelet volume be used as a predictor of vascular disease? Problems and pitfalls. Semin Thromb Hemost 2017;43:599–608.

[43] Yilmaz MB, Saricam E, Biyikoglu SF, et al. Mean platelet volume and exercise stress test. J Thromb Thrombolysis 2004;17:115–20.